No headlines found.
Palatin to Begin Trading on Nasdaq Stock Exchange
PRNewswire (Mon, 18-May 4:00 PM ET)
Palatin Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
PRNewswire (Wed, 13-May 7:30 AM ET)
Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system. The product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical needs and commercial potential. The Company's business is in one operating segment: life science.
Palatin Techs trades on the NASDAQ stock market under the symbol PTN.
As of June 2, 2026, PTN stock price declined to $13.90 with 19,160 million shares trading.
PTN has a market cap of $24.73 million. This is considered a Sub-Micro Cap stock.
Last quarter Palatin Techs reported $4 million in Revenue and -$.37 earnings per share. This beat revenue expectation by $3 million and exceeded earnings estimates by $.45.
The top ETF exchange traded funds that PTN belongs to (by Net Assets): VXF.
PTN support price is $13.65 and resistance is $15.57 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PTN shares will trade within this expected range on the day.
